<DOC>
	<DOC>NCT00695435</DOC>
	<brief_summary>To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.</brief_summary>
	<brief_title>Tobramycin Tear Concentrations</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Inclusion: Visual Acuity (VA) of 0.6 logMAR or better Tear meniscus height of ≥ 0.3mm at Visit 1. No concomitant topical ocular medications, including artificial tears, during the study period Exclusion ocular hypertension, iritis or uveitis, glaucoma ocular surgery, intraocular surgery or ocular laser procedures in either eye within the past six months epithelial herpes simplex (dendritic keratitis); Vaccinia, active or recent varicella viral disease of the cornea and/or conjunctiva; ocular Rosacea; Mycobacterial infection of the eye; and / or fungal disease of the eye lacrimal duct obstruction, dry eye, ocular allergies. contact lens within 7 days of Visit 1. ocular medications within 14 days of Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>normal volunteers</keyword>
	<keyword>anti-infective</keyword>
	<keyword>tobramycin</keyword>
</DOC>